Join the Oncology Voice Network. Join for Free
Repackage what you have for what you want
MSL career transition MSL capability continuum post-pandemic MSL landscape MSL digital proficiency MSL certification programs

Repackage what you have for what you want


Share This Article


Summary

In this episode, Cherie Hyder shares her journey from the FDA to the industry, discussing the transition and how to enhance skills for a successful MSL career. She emphasizes the importance of documenting experience and understanding the MSL role, highlighting the MSL capability continuum and certification programs. Cherie discusses the significance of soft skills and digital proficiency, along with predictions for the post-pandemic MSL landscape. She offers insights into effective email communication, evolving metrics, and the critical role of insight gathering. The episode wraps up with best practices for post-meeting note-taking and career development strategies.

Check out my latest podcast with Cherie Hyder, Medical Excellence at Biohaven who discusses how to repackage what you have for what you want.

Cherie shares…. 

 How to position yourself for MSL roles

 Tool and resources to be aware of

 How to showcase important skills and traits

 Certification programs and if they are worth it

 Mandatory skills for the MSL of the future

Click for Source
MSL career transition, MSL capability continuum, post-pandemic MSL landscape, MSL digital proficiency, MSL certification programs

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Mastering the Medical Affairs Professional Role: Inside and Out
Partner Avatar MSL Talk: Tom Caravela, Kent Christofferson

Mastering the Medical Affairs Professional Role: Inside and Out

Podcast
Landing My First MSL Role: From the Inside
Partner Avatar MSL Talk: Tom Caravela, Amanda Vaughn

Landing My First MSL Role: From the Inside

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Explore OVN